World Pharmaceutical Contract Manufacturing Market

World Pharmaceutical Contract Manufacturing Market

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in Millions of US$. The Major product segments anaylzed are Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid Dosage Forms (Syrups and Suspensions). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 84 companies including many key and niche players worldwide such as Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd., HAUPT Pharma AG, Jubilant Organosys Ltd., Kemwell Pvt. Ltd., NextPharma, Nipro Corp., Patheon, Inc., Penn Pharmaceutical Services Ltd., and Royal DSM N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources

PHARMACEUTICAL CONTRACT MANUFACTURING MCP-1535
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. Market Dynamics II-1
An Insight into the Rise of PCM II-1
Industry Potential II-1

2. Service Overview II-3
Introduction II-3
Injectables (injections, vials, and IV solutions) II-3
Solid Dosage Forms (SDFs) (Tablets and Capsules) II-3
Liquid Dosage Forms (LDFs) (Syrups and Suspensions) II-4
A Focus on Bio-Manufacturing II-4

3. Trends & Issues II-5
Outsourcing Emerges as a Strategic Priority for Pharmaceutical
Companies II-5
Asia Dominates Regional Growth, North America Retains Position
as Largest Market II-5
Virtual Pharma vs. Blockbuster Model II-6
Investment Risks in Pharmaceutical Contract Quality Assurance
Risk II-6
Drug Development Risk II-6
Acquisition Risk II-6
Client Dependency Risk II-6

4. Recent Industry Activity II-7
Jubilant Acquires Draxis for US$ 253 Million II-7
JHP Acquires Assets of King Pharmaceuticals II-7
NextPharma Acquires Bioserv Corporation II-7
Dr. Reddy’s to Acquire Dowpharma’s Facilities II-8
PharmAthene to Acquire Avecia’s Biodefense Vaccine Operations II-8
Bioserv Enters into an Outsourcing Agreement with BioLife
Solutions II-9
Eden Biodesign and Stealthyx Therapeutics Ink an Agreement II-9
NPIL Pharma to Expand HPS Sites in Scotland II-9
Dishman Pharma Installs New API Facilities II-9
Patheon Divests Niagara-Burlington Manufacturing Business to
Pharmetics II-10
Jubilant Organosys Acquires Hollister-Stier Laboratories II-10
Hikma Pharmaceuticals Acquires Thymoorgan GmbH Pharmazie II-10
Meda Acquires Recip II-11
Keata Pharma to Acquire Pfizer’s Production Facility in Canada II-11
STADA Acquires MAKIZ II-12
Nextpharma to Expand its Cytostatics Production Facility II-12
Haupt Pharma Establishes Production Facility in Malta II-12
Kemwell Pockets Pfizer’s Uppsala Sweden Based Manufacturing Plant II-13
Crucell and DSM Biologics Enter into a Licensing Agreement
with UMN Pharma II-13
Lannett Inks a Multi-Product Contract Manufacturing Agreement
with Wintac II-13
ATOZ Establishes Soft Gelatin Manufacturing Facility in
Himachal Pradesh, India II-14
BASF Buys Orgamol SA II-14
Federa Completes Construction of Prefilled Syringes Facility II-14
BioProgress PLC Signs an Agreement with Custom Pharmaceuticals II-14
Safeguard Scientifics Acquires Laureate II-14
Patheon Buys MOVA Pharmaceutical II-14
Nichi-iko Strikes a Deal with Maruko Pharmaceutical II-15
DRAXIS Health Acquires Minority Stake in DRAXIS Pharma II-15
WPCC Receives FDA Acceptance II-15
Dechra Pharmaceuticals Acquires Anglian Pharma II-15

5. Focus on Select Global Players II-16
Althea Technologies (USA) II-16
Catalent Pharma Solutions (USA) II-16
Dishman Pharmaceuticals and Chemicals Ltd (India) II-16
HAUPT Pharma AG (Germany) II-16
Jubilant Organosys Ltd (India) II-17
Kemwell Pvt. Ltd (India) II-17
NextPharma (UK) II-17
Nipro Corp (Japan) II-17
Patheon, Inc. (Canada) II-17
Penn Pharmaceutical Services Ltd (UK) II-18
Royal DSM N.V. (Netherlands) II-18

6. Global Market Perspective II-19
Table 1: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Geographic Region -
USA, Canada, Japan, Europe, Asia-Pacific and Rest of World
Independently Analyzed by Annual Sales in US$ Million for the
Years 2000 through 2010 (includes corresponding Graph/Chart) II-19

Table 2: World Long-Term Projections for Pharmaceutical
Contract Manufacturing by Geographic Region - USA, Canada,
Japan, Europe, Asia-Pacific and Rest of World Independently
Analyzed by Annual Sales in US$ Million for the Years 2011
through 2015 (includes corresponding Graph/Chart) II-20

Table 3: World 10-Year Perspective for Pharmaceutical Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific and
Rest of World for the Years 2003, 2008 and 2012 (includes
corresponding Graph/Chart) II-21

Table 4: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Injectables
(Injections, Vials & Intravenous Solutions) by Geographic
Region - USA, Canada, Japan, Europe, Asia-Pacific and Rest of
World Independently Analyzed by Annual Sales in US$ Million
for the Years 2000 through 2010 (includes corresponding
Graph/Chart) II-22

Table 5: World Long-Term Projections for Pharmaceutical
Contract Manufacturing of Injectables (Injections, Vials &
Intravenous Solutions) by Geographic Region - USA, Canada,
Japan, Europe, Asia-Pacific and Rest of World Independently
Analyzed by Annual Sales in US$ Million for the Years 2011
through 2015 (includes corresponding Graph/Chart) II-23

Table 6: World 10-Year Perspective for Pharmaceutical Contract
Manufacturing of Injectables (Injections, Vials & Intravenous
Solutions) by Geographic Region - Percentage Breakdown of
Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific and
Rest of World for the Years 2003, 2008 and 2012 (includes
corresponding Graph/Chart) II-24

Table 7: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Solid Dosage Forms
(Tablets & Capsules) by Geographic Region - USA, Canada,
Japan, Europe, Asia-Pacific and Rest of World Independently
Analyzed by Annual Sales in US$ Million for the Years 2000
through 2010 (includes corresponding Graph/Chart) II-25

Table 8: World Long-Term Projections for Pharmaceutical
Contract Manufacturing of Solid Dosage Forms (Tablets &
Capsules) by Geographic Region - USA, Canada, Japan, Europe,
Asia-Pacific and Rest of World Independently Analyzed by
Annual Sales in US$ Million for the Years 2011 through 2015
(includes corresponding Graph/Chart) II-26

Table 9: World 10-Year Perspective for Pharmaceutical Contract
Manufacturing of Solid Dosage Forms (Tablets & Capsules) by
Geographic Region - Percentage Breakdown of Dollar Sales for
USA, Canada, Japan, Europe, Asia-Pacific and Rest of World for
the Years 2003, 2008 and 2012 (includes corresponding
Graph/Chart) II-27

Table 10: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Liquid Dosage Forms
(Syrups & Suspensions) by Geographic Region - USA, Canada,
Japan, Europe, Asia-Pacific and Rest of World Independently
Analyzed by Annual Sales in US$ Million for the Years 2000
through 2010 (includes corresponding Graph/Chart) II-28

Table 11: World Long-Term Projections for Pharmaceutical
Contract Manufacturing of Liquid Dosage Forms (Syrups &
Suspensions) by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific and Rest of World Independently Analyzed
by Annual Sales in US$ Million for the Years 2011 through 2015
(includes corresponding Graph/Chart) II-29

Table 12: World 10-Year Perspective for Pharmaceutical
Contract Manufacturing of Liquid Dosage Forms (Syrups &
Suspensions) by Geographic Region - Percentage Breakdown of
Dollar Sales for USA, Canada, Japan, Europe, Asia- Pacific and
Rest of World for the Years 2003, 2008 and 2012 (includes
corresponding Graph/Chart) II-30


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Trends III-1
Pharma Companies Increasingly Outsource Manufacturing Activity III-1
Injectables Segment Witnesses Upward Growth Trend III-1
Competitive Landscape III-1
Strategic Corporate Developments III-2
Key Players III-4
Althea Technologies III-4
Catalent Pharma Solutions III-5
B.Market Analytics III-5
Table 13: US Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Product Segment -
Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed by
Annual Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) III-5

Table 14: US Long-Term Projections for Pharmaceutical
Contract Manufacturing by Product Segment - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed by Annual Sales in US$
Million for the Years 2011 through 2015 (includes
corresponding Graph/Chart) III-6

Table 15: US 10-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Segment - Percentage Breakdown of
Dollar Sales for Injectables (Injections, Vials &
Intravenous Solutions), Solid Dosage Forms (Tablets &
Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for
the Years 2003, 2008 and 2012 (includes corresponding
Graph/Chart) III-6

2. Canada III-7
A.Market Analysis III-7
Current and Future Analysis III-7
Strategic Developments III-7
Patheon, Inc. - A Key Canadian Player III-8
B.Market Analytics III-9
Table 16: Canadian Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Product Segment
- Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed by
Annual Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) III-9

Table 17: Canadian Long-Term Projections for Pharmaceutical
Contract Manufacturing by Product Segment - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed by Annual Sales in US$
Million for the Years 2011 through 2015 (includes
corresponding Graph/Chart) III-10

Table 18: Canadian 10-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Segment - Percentage
Breakdown of Dollar Sales for Injectables (Injections,
Vials & Intravenous Solutions), Solid Dosage Forms (Tablets
& Capsules) and Liquid Dosage Forms (Syrups & Suspensions)
for the Years 2003, 2008 and 2012 (includes corresponding
Graph/Chart) III-10

3. Japan III-11
A.Market Analysis III-11
Current and Future Analysis III-11
Impact of Contract Manufacturing on Japanese Pharmaceutical
Sector III-11
Nipro Corp - A Key Japanese Player III-11
B.Market Analytics III-12
Table 19: Japanese Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Product Segment
- Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed by
Annual Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) III-12

Table 20: Japanese Long-Term Projections for Pharmaceutical
Contract Manufacturing by Product Segment - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed by Annual Sales in US$
Million for the Years 2011 through 2015 (includes
corresponding Graph/Chart) III-13

Table 21: Japanese 10-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Segment - Percentage
Breakdown of Dollar Sales for Injectables (Injections, Vials
& Intravenous Solutions), Solid Dosage Forms (Tablets &
Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for
the Years 2003, 2008 and 2012 (includes corresponding
Graph/Chart) III-13

4. Europe III-14
A.Market Analysis III-14
Current and Future Analysis III-14
Trend III-14
Injectables Segment Offers Promising Potential III-14
Competitive Scenario III-14
Strategic Corporate Developments III-14
Key European Players III-19
HAUPT Pharma AG (Germany) III-19
NextPharma (UK) III-19
Penn Pharmaceutical Services Ltd (UK) III-19
Royal DSM N.V. (Netherlands) III-20
B.Market Analytics III-20
Table 22: European Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Product Segment
- Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed by
Annual Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) III-20

Table 23: European Long-Term Projections for Pharmaceutical
Contract Manufacturing by Product Segment - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed by Annual Sales in US$
Million for the Years 2011 through 2015 (includes
corresponding Graph/Chart) III-21

Table 24: European 10-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Segment - Percentage
Breakdown of Dollar Sales for Injectables (Injections,
Vials & Intravenous Solutions), Solid Dosage Forms (Tablets
& Capsules) and Liquid Dosage Forms (Syrups & Suspensions)
for the Years 2003, 2008 and 2012 (includes corresponding
Graph/Chart) III-21

5. Asia-Pacific III-22
A.Market Analysis III-22
Current and Future Analysis III-22
Trends III-22
Upbeat Market for Pharmaceutical Contract Manufacturing III-22
Competitive Scenario III-22
India III-22
Strategic Developments III-23
Select Players III-25
Dishman Pharmaceuticals and Chemicals Ltd (India) III-25
Jubilant Organosys Ltd (India) III-25
Kemwell Pvt. Ltd (India) III-26
B.Market Analytics III-26
Table 25: Asia-Pacific Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by
Product Segment - Injectables (Injections, Vials &
Intravenous Solutions), Solid Dosage Forms (Tablets &
Capsules) and Liquid Dosage Forms (Syrups & Suspensions)
Independently Analyzed by Annual Sales in US$ Million for
the Years 2000 through 2010 (includes corresponding
Graph/Chart) III-26

Table 26: Asia-Pacific Long-Term Projections for
Pharmaceutical Contract Manufacturing by Product Segment -
Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed by
Annual Sales in US$ Million for the Years 2011 through 2015
(includes corresponding Graph/Chart) III-27

Table 27: Asia-Pacific 10-Year Perspective for
Pharmaceutical Contract Manufacturing by Product Segment -
Percentage Breakdown of Dollar Sales for Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups
& Suspensions) for the Years 2003, 2008 and 2012 (includes
corresponding Graph/Chart) III-27

6. Rest of World III-28
Market Analysis III-28
Table 28: Rest of World Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by
Product Segment - Injectables (Injections, Vials &
Intravenous Solutions), Solid Dosage Forms (Tablets &
Capsules) and Liquid Dosage Forms (Syrups & Suspensions)
Independently Analyzed by Annual Sales in US$ Million for
the Years 2000 through 2010 (includes corresponding
Graph/Chart) III-28

Table 29: Rest of World Long-Term Projections for
Pharmaceutical Contract Manufacturing by Product Segment -
Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed by
Annual Sales in US$ Million for the Years 2011 through 2015
(includes corresponding Graph/Chart) III-29

Table 30: Rest of World 10-Year Perspective for
Pharmaceutical Contract Manufacturing by Product Segment -
Percentage Breakdown of Dollar Sales for Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups
& Suspensions) for the Years 2003, 2008 and 2012 (includes
corresponding Graph/Chart) III-29


IV. COMPETITIVE LANDSCAPE


The Companies Mentioned inside this Report include: Abbott- Biologics & Pharmaceutical Contract Manufacturing (USA)
Akorn, Inc (USA)
Althea Technologies (USA)
AMCAPHARM Pharmaceutical GmbH (Germany)
Apoteket AB Produktion & Laboratorier (APL)
(Sweden)
Applied Laboratories, Inc (USA)
ATOZ Pharmaceuticals (India)
Baccinex SA (Switzerland)
BASF Pharma Solutions (Germany)
Baxter BioPharma Solutions (USA)
Beltapharm SpA (Italy)
Ben Venue Laboratories, Inc (USA)
BioInvent International AB (Sweden)
BioProgress PLC (UK)
BioZone Laboratories, Inc (USA)
Bluepharma (Portugal)
Brawn Laboratories Ltd (India)
Bushu Pharmaceuticals Ltd (Japan)
Cardinal Health, Inc (USA)
Celltech Manufacturing Services Ltd (UK)
Cenexi, Roche Group (France)
Ciron Drugs & Pharmaceuticals (P)
Ltd (India)
Confab Laboratories, Inc (Canada)
Cook Pharmica LLC (USA)
Crucell NV (The Netherlands)
Custom Pharmaceuticals Ltd (UK)
Dalton Pharma Services (Canada)
Delpharm (France)
Dishman Pharmaceuticals and Chemicals Ltd (India)
Dragenopharm GmbH & Co KG (Germany)
Draxis Health, Inc (Canada)
DSM Biologics (USA)
Fine Foods NTM SpA (Italy)
Fuji Chemical Industry Co, Ltd (Japan)
Hasco-Lek SA (Poland)
Haupt Pharma Ag (Germany)
Hikal Ltd (India)
Hollister-Stier Laboratories LLC (USA)
Keata Pharma, Inc (Canada)
Kemwell Pvt Ltd (India)
Laboratoires Panpharma SA (France)
Lannett Company, Inc (USA)
Laureate Pharma, Inc (USA)
Lipa Pharmaceuticals (Australia)
Lomapharm (Germany)
Lyka Labs (India)
Lyne Laboratories (USA)
Mallinckrodt Pharmaceuticals (USA)
Matrix Laboratories Limited (India)
McGuff Pharmaceuticals, Inc (USA)
Medico Labs, Inc (USA)
Meridian Enterprises Pvt, Ltd (India)
MP-Technopharma Corporation (Japan)
NextPharma Technologies (UK)
P J Noyes Co, Inc (USA)
Patheon, Inc (Canada)
Penn Pharmaceutical Services Limited (UK)
Perrigo Company (USA)
PharmaFab (USA)
Pierrel SpA (Italy)
Radico Remedies (India)
Recipharm Contract Manufacturing (Sweden)
Reliable Biopharmaceutical Corporation (USA)
Sphere Healthcare Pty, Ltd (Australia)
Stason Pharmaceuticals, Inc (USA)
Temmler Pharma GmbH & Co, KG (Germany)
The Chao Center (USA)
Therapex (Canada)
Tropon GmbH (Germany)
United Biomedical, Inc (USA)
UPM Pharmaceuticals (USA)
Vista Biologicals Co (USA)
Weimer Pharma GmbH (Germany)
Wellspring Pharmaceutical Co (USA)
Well Spring Pharmaceutical Canada Corporation (Canada)
Whyte International Limited (UK)
Wintac Limited (India)
Wockhardt UK Limited (UK)
Zambon Group SpA (Italy)
Zydus Cadila (India)